Mechanism of platelet activation induced by endocannabinoids in blood and plasma

Platelets

Volumn 25, Issue 3, 2014, Pages 151-161

  Brantl, S Annette ^a   Khandoga, Anna L ^a   Siess, Wolfgang ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

2 Arachidonoylglycerol; Anandamide; Cyclooxygenase; Endocannabinoid; Monoacylglycerol lipase; Platelet; Virodhamine

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CYCLOOXYGENASE 1; DALTROBAN; ESTERASE INHIBITOR; JZL L184; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR; THROMBOXANE SYNTHASE; UNCLASSIFIED DRUG; VIRODHAMINE; 2-ARACHIDONYLGLYCEROL; ACYLGLYCEROL; AMIDE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID DERIVATIVE; CANNABINOID; ENDOCANNABINOID;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOCYTE SHAPE; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

ADULT; ARACHIDONIC ACIDS; BLOOD PLATELETS; CANNABINOIDS; CYCLOOXYGENASE 1; ENDOCANNABINOIDS; GLYCERIDES; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; POLYUNSATURATED ALKAMIDES;

EID: 84925222792     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.803530     Document Type: Article

References (56)

1. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58: 389-462.
2. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006;45:405-446.
3. Mach F, Montecucco F, Steffens S. Cannabinoid receptors in acute and chronic complications of atherosclerosis. Br J Pharmacol 2008; 153:290-298.
4. Randall MD, Kendall DA, O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004;142: 20-26.
5. De Petrocellis L, Di Marzo V. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimi-metics: Focus on G-protein-coupled receptors and transient receptor potential channels. J Neuroimmune Pharmacol 2010;5:103-121.
6. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005;434:782-786.
7. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA 2008;299: 1547-1560.
8. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 2009;46:612-620.
9. Hoyer FF, Steinmetz M, Zimmer S, Becker A, Lutjohann D, Buchalla R, Zimmer A, Nickenig G. Atheroprotection via canna-binoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 2011;51:1007-1014.
10. Steffens S, Pacher P. Targeting cannabinoid receptor CB(2) in cardiovascular disorders: Promises and controversies. Br J Pharmacol 2012;167:313-323.
11. Dol-Gleizes F, Paumelle R, Visentin V, Mares AM, Desitter P, Hennuyer N, Gilde A, Staels B, Schaeffer P, Bono F. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Throm Vasc Biol 2009;29:12-18.
12. Montecucco F, Di Marzo V. At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci 2012;33:331-340.
13. Zoerner AA, Gutzki FM, Batkai S, May M, Rakers C, Engeli S, Jordan J, Tsikas D. Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: A comprehensive review from an analytical and biological perspective. Biochim Biophys Acta 2011;1811:706-723.
14. Sugamura K, Sugiyama S, Nozaki T, Matsuzawa Y, Izumiya Y, Miyata K, Nakayama M, Kaikita K, Obata T, Takeya M, et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 2009;119:28-36.
15. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011;32: 1369-1378.
16. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, et al. Production and physiological actions of anandamide in the vascu-lature of the rat kidney. J Clin Invest 1997;100:1538-1546.
17. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet-And macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998;12:1035-1044.
18. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, Goparaju SK, Kunos G, Ertl G. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol 2001;38:2048-2054.
19. Prescott SM, Majerus PW. Characterization of 1, 2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol Chem 1983;258:764-769.
20. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S, Pagano S, Piscitelli F, Quintao S, Bertolotto M, et al. The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 2012;33:846-856.
21. Maeda N, Osanai T, Kushibiki M, Fujiwara T, Tamura Y, Oowada S, Higuma T, Sasaki S, Yokoyama J, Yoshimachi F, et al. Increased serum anandamide level at ruptured plaque site in patients with acute myocardial infarction. Fundam Clin Pharmacol 2009;23: 351-357.
22. Catani MV, Gasperi V, Catanzaro G, Baldassarri S, Bertoni A, Sinigaglia F, Avigliano L, Maccarrone M. Human platelets express authentic CB1 and CB2 receptors. Curr Neurovasc Res 2010;7: 311-318.
23. Maccarrone M, Bari M, Menichelli A, Del Principe D, Agro AF. Anandamide activates human platelets through a pathway independent of the arachidonate cascade. FEBS Lett 1999;447:277-282.
24. Braud S, Bon C, Touqui L, Mounier C. Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. FEBS Lett 2000;471:12-16.
25. Fasia L, Karava V, Siafaka-Kapadai A. Uptake and metabolism of [3H]anandamide by rabbit platelets. Lack of transporter? Eur J Biochem 2003;270:3498-3506.
26. Maccarrone M, Bari M, Menichelli A, Giuliani E, Del Principe D, Finazzi-Agro A. Human platelets bind and degrade 2-Arachidonoyl-glycerol, which activates these cells through a cannabinoid receptor. Eur J Biochem 2001;268:819-825.
27. Malorni W, Bari M, Straface E, Battista N, Matarrese P, Finazzi-Agro A, Del Principe D, Maccarrone M. Morphological evidence that 2-Arachidonoylglycerol is a true agonist of human platelets. Thromb Haemost 2004;92:1159-1161.
28. Baldassarri S, Bertoni A, Bagarotti A, Sarasso C, Zanfa M, Catani MV, Avigliano L, Maccarrone M, Torti M, Sinigaglia F. The endocannabinoid 2-Arachidonoylglycerol activates human platelets through non-CB1/CB2 receptors. J Thromb Haemost 2008;6: 1772-1779.
29. Signorello MG, Giacobbe E, Leoncini G. Activation by 2- Arachidonoylglycerol of platelet p38MAPK/cPLA2 pathway. J Cell Biochem 2011;112:2794-2802.
30. Gkini E, Anagnostopoulos D, Mavri-Vavayianni M, Siafaka-Kapadai A. Metabolism of 2-Acylglycerol in rabbit and human platelets. Involvement of monoacylglycerol lipase and fatty acid amide hydrolase. Platelets 2009;20:376-385.
31. Keown OP, Winterburn TJ, Wainwright CL, Macrury SM, Neilson I, Barrett F, Leslie SJ, Megson IL. 2-Arachidonyl glycerol activates platelets via conversion to arachidonic acid and not by direct activation of cannabinoid receptors. Br J Clin Pharmacol 2010;70: 180-188.
32. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002; 301:1020-1024.
33. Siess W, Lapetina EG. Phorbol esters sensitize platelets to activation by physiological agonists. Blood 1987;70:1373-1381.
34. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-788.
35. Negrescu EV, de Quintana KL, Siess W. Platelet shape change induced by thrombin receptor activation. Rapid stimulation of tyrosine phosphorylation of novel protein substrates through an integrin-And Ca(2)-independent mechanism. J Biol Chem 1995; 270:1057-1061.
36. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavon FJ, Serrano AM, Selley DE, Parsons LH, et al. Selective blockade of 2-Arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009;5:37-44.
37. Penz SM, Bernlochner I, Toth O, Lorenz R, Calatzis A, Siess W. Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J 2010;8:9.
38. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989;69:58-178.
39. Siess W, Siegel FL, Lapetina EG. Arachidonic acid stimulates the formation of 1, 2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation. J Biol Chem 1983;258:11236-11242.
40. Maschberger P, Bauer M, Baumann-Siemons J, Zangl KJ, Negrescu EV, Reininger AJ, Siess W. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2 influx in human platelets. J Biol Chem 2000;275:19159-19166.
41. Maccarrone M, Bari M, Del Principe D, Finazzi-Agro A. Activation of human platelets by 2-Arachidonoylglycerol is enhanced by serotonin. Thromb Haemost 2003;89:340-347.
42. Yapa U, Prusakiewicz JJ, Wrightstone AD, Christine LJ, Palandra J, Groeber E, Wittwer AJ. High-performance liquid chromatography-tandem mass spectrometry assay of fatty acid amide hydrolase (FAAH) in blood: FAAH inhibition as clinical biomarker. Anal Biochem 2012;421:556-565.
43. Signorello MG, Giacobbe E, Segantin A, Avigliano L, Sinigaglia F, Maccarrone M, Leoncini G. Activation of human platelets by 2- Arachidonoylglycerol: Role of PKC in NO/cGMP pathway modulation. Curr Neurovasc Res 2011;8:200-209.
44. Fielding CJ. Monoglyceride hydrolase activities of rat plasma and platelets. Their properties and roles in the activity of lipoprotein lipase. J Biol Chem 1981;256:876-881.
45. Lichtman AH, Blankman JL, Cravatt BF. Endocannabinoid overload. Mol Pharmacol 2010;78:993-995.
46. Siess W, Weber PC, Lapetina EG. Activation of phospholipase C is dissociated from arachidonate metabolism during platelet shape change induced by thrombin or platelet-Activating factor. Epinephrine does not induce phospholipase C activation or platelet shape change. J Biol Chem 1984;259:8286-8292.
47. Thomas A, Hopfgartner G, Giroud C, Staub C. Quantitative and qualitative profiling of endocannabinoids in human plasma using a triple quadrupole linear ion trap mass spectrometer with liquid chromatography. Rapid Commun Mass Spectrom 2009;23:629-638.
48. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Almeras N, Despres JP. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors. Diabetologia 2009;52:213-217.
49. Haseruck N, Erl W, Pandey D, Tigyi G, Ohlmann P, Ravanat C, Gachet C, Siess W. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: Involvement of P2Y1 and P2Y12 receptors. Blood 2004;103:2585-2592.
50. Rother E, Brandl R, Baker DL, Goyal P, Gebhard H, Tigyi G, Siess W. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003;108:741-747.
51. Ko YG, Jung JH, Park S, Choi E, Joung B, Hwang KC, Ha JW, Choi D, Jang Y, Chung N, et al. Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol 2006;112:66-71.
52. Hjemdahl P, Larsson PT, Wallen NH. Effects of stress and beta-blockade on platelet function. Circulation 1991;84(Suppl. 6): VI44-VI61.
53. Siess W, Lorenz R, Roth P, Weber PC. Plasma catecholamines, platelet aggregation and associated thromboxane formation after physical exercise, smoking or norepinephrine infusion. Circulation 1982;66:44-48.
54. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K. Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: Implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol 2012;81:250-263.
55. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: Potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011;36:10-18.
56. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009;330:902-910.